Comprehensive multi-omics analysis showed that CDC6 is a potential prognostic and immunotherapy biomarker for multiple cancer types including HCC

IF 5 2区医学 Q2 Medicine Translational Oncology Pub Date : 2025-03-01 Epub Date: 2025-02-03 DOI:10.1016/j.tranon.2025.102314

Chenxuan Li , En-di Zhang , Rui Yu, Bo Yuan, Yunxin Yang, Zhong Zeng, Hanfei Huang

{"title":"Comprehensive multi-omics analysis showed that CDC6 is a potential prognostic and immunotherapy biomarker for multiple cancer types including HCC","authors":"Chenxuan Li , En-di Zhang , Rui Yu, Bo Yuan, Yunxin Yang, Zhong Zeng, Hanfei Huang","doi":"10.1016/j.tranon.2025.102314","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Cell division cycle 6 (CDC6) is a member of the AAA+ ATPase family and has chaperone-like activity. Many studies have shown that CDC6 plays an important role in cancer development and progression.</div></div><div><h3>Methods</h3><div>Explored CDC6 mRNA and protein expression in normal human tissues and tumors using TCGA, GTEx, and HPA. The role of CDC6 in cancer was analyzed using multiple web platforms and software, including R, cBioPortal, UALCAN, SangerBox and others. Finally, CCK-8, EdU assays and Transwell assays were used to verify the effects of CDC6 knockdown on HCC cell proliferation, migration, and invasion.</div></div><div><h3>Results</h3><div>CDC6 expression was upregulated in most cancers and was associated with poorer prognosis. RNA methylation may play an important role in CDC6 epigenetic modification. CDC6 was significantly positively associated with CD4+ Th2 cells and MDSC in a variety of tumors. Furthermore, immunomodulatory genes are strongly associated with CDC6 expression in most tumor types. CDC6 has higher predictive value than B. Clonality and TMB, and its expression is significantly positively correlated with TMB/MSI and DNAss/RNAss, and is closely related to cell cycle events. Down-regulation of CDC6 can inhibit proliferation, migration and invasion of HCC cells.</div></div><div><h3>Conclusions</h3><div>CDC6 is associated with the occurrence and progression of multiple cancer types by regulating the cell cycle. It holds promise as a diagnostic and prognostic biomarker for cancer, and offers potential in immunomodulatory and targeted therapies.</div></div>","PeriodicalId":48975,"journal":{"name":"Translational Oncology","volume":"53 ","pages":"Article 102314"},"PeriodicalIF":5.0000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1936523325000452","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/3 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Cell division cycle 6 (CDC6) is a member of the AAA+ ATPase family and has chaperone-like activity. Many studies have shown that CDC6 plays an important role in cancer development and progression.

Methods

Explored CDC6 mRNA and protein expression in normal human tissues and tumors using TCGA, GTEx, and HPA. The role of CDC6 in cancer was analyzed using multiple web platforms and software, including R, cBioPortal, UALCAN, SangerBox and others. Finally, CCK-8, EdU assays and Transwell assays were used to verify the effects of CDC6 knockdown on HCC cell proliferation, migration, and invasion.

Results

CDC6 expression was upregulated in most cancers and was associated with poorer prognosis. RNA methylation may play an important role in CDC6 epigenetic modification. CDC6 was significantly positively associated with CD4+ Th2 cells and MDSC in a variety of tumors. Furthermore, immunomodulatory genes are strongly associated with CDC6 expression in most tumor types. CDC6 has higher predictive value than B. Clonality and TMB, and its expression is significantly positively correlated with TMB/MSI and DNAss/RNAss, and is closely related to cell cycle events. Down-regulation of CDC6 can inhibit proliferation, migration and invasion of HCC cells.

Conclusions

CDC6 is associated with the occurrence and progression of multiple cancer types by regulating the cell cycle. It holds promise as a diagnostic and prognostic biomarker for cancer, and offers potential in immunomodulatory and targeted therapies.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

多组学综合分析表明，CDC6 是包括 HCC 在内的多种癌症类型的潜在预后和免疫疗法生物标记物

细胞分裂周期6 （CDC6）是AAA+ atp酶家族的一员，具有伴侣样活性。许多研究表明，CDC6在癌症的发生和发展中起着重要作用。方法采用TCGA、GTEx和HPA检测正常人组织和肿瘤中CDC6 mRNA和蛋白的表达。使用多种网络平台和软件，包括R、cbiopportal、UALCAN、SangerBox等，分析CDC6在癌症中的作用。最后，通过CCK-8、EdU和Transwell实验验证CDC6敲低对HCC细胞增殖、迁移和侵袭的影响。结果scdc6在大多数肿瘤中表达上调，且与预后较差相关。RNA甲基化可能在CDC6表观遗传修饰中起重要作用。CDC6在多种肿瘤中与CD4+ Th2细胞和MDSC呈显著正相关。此外，在大多数肿瘤类型中，免疫调节基因与CDC6表达密切相关。CDC6的预测价值高于B.克隆性和TMB，其表达与TMB/MSI和dnas /RNAss显著正相关，与细胞周期事件密切相关。下调CDC6可抑制HCC细胞的增殖、迁移和侵袭。结论scdc6通过调控细胞周期与多种肿瘤的发生发展相关。它有望作为癌症的诊断和预后生物标志物，并在免疫调节和靶向治疗中提供潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Translational Oncology ONCOLOGY-

CiteScore

8.40

自引率

2.00%

发文量

314

审稿时长

54 days

期刊介绍： Translational Oncology publishes the results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of oncology patients. Translational Oncology will publish laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer. Peer reviewed manuscript types include Original Reports, Reviews and Editorials.